Educational research & price index · Independent Janoshik & MZ Biolabs COA verification

← Verified COAs & $/mg for this compound

Guide|20 CitationsHormonal & GHFemale-friendly

CJC-1295 (No DAC / Mod GRF 1-29) Research Dosing Reference

Also known as: Mod GRF (1-29), CJC-1295 Without DAC, CJC-1295 DAC

Dose Range
100–200 mcgResearch range
0Typical research window: 100–200 mcg300 mcg

Studied in human endocrine trials (JCEM PMID: 16352683). Mod GRF 1-29 (No DAC) is typically dosed at 100 mcg per injection alongside Ipamorelin.

Protocol at a Glance
How Often
1–2× daily

100 mcg 1–2× daily (Mod GRF 1-29 No DAC) on an empty stomach

A Typical Run
8–12 weeks

5 days on / 2 days off for 8–12 weeks, then 4 weeks off.

How It's Taken
Vial

SubQ injection (often stacked 1:1 with Ipamorelin)

Evidence
Clinical Trials

Human endocrine clinical studies (Teichman et al., JCEM)

Half-Life & 72-Hour Clearance Shape
~30 min

~30 min for CJC-1295 No DAC (Mod GRF 1-29); preserves physiological GH pulse trough

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 100 mcg4 units
High end: 200 mcg8 units

All U-100: 100 units = 1 mL. 50 doses in the vial at the low end (25 doses at the high end).

Track the doses you run

Save CJC-1295 (No DAC / Mod GRF 1-29) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

CJC-1295 (No DAC / Mod GRF 1-29) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$60.00
10mg CJC-1295 no DAC / Ipamorelin 5/5mg
$6.00/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$119.99
20mg CJC-1295 no DAC / Ipamorelin 10/10mg
$6.00/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$70.00
10mg vial
$7.00/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$99.00
10mg CJC-1295 no DAC / Ipamorelin 5/5mg
$9.90/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$99.97
10mg CJC-1295 no DAC + Ipamorelin
$10.00/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Pituitary Growth Hormone Secretagogue (GHRH Analog / Ghrelin Receptor Agonist)
Administration Route
Under-the-skin injection (Subcutaneous)
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a Growth Hormone Secretagogue?

A compound that stimulates your pituitary gland to release more of its own growth hormone (GH). Unlike synthetic GH injection, secretagogues trigger natural pulsatile GH release. Examples: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin. MK-677 (Ibutamoren) is technically not a peptide but acts as an oral GH secretagogue.

Bottom Line Up Front

CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that stimulates pulsatile GH release. It has a longer half-life than natural GHRH due to DAC (drug affinity complex). Human studies show sustained increases in GH and IGF-1.

Best evidence for

Growth hormone deficiency, muscle preservation

Weakest evidence for

Fat loss in healthy adults, anti-aging

Pharma equivalent

None

Studies on file

20 (11 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. CJC-1295 (No DAC / Mod GRF 1-29) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) version extends its half-life. Research has examined its effects on growth hormone secretion.

Mechanisms of Action

  • Stimulates GH release from pituitary
  • Extended half-life with DAC
  • Increases IGF-1 levels
  • Pulsatile GH secretion pattern

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
GH Secretion Study
reported protocol
30 μg/kgWeekly4 weeksSubcutaneoushuman
Baseline & Mid-Cycle Biomarker Bloodwork Panel

GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (CJC-1295 (No DAC / Mod GRF 1-29))

Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

Serum IGF-1 (LC/MS) + Z-Score

Day 0 + Wk 6–8

Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.

Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).

Fasting Insulin & HOMA-IR

Day 0 + Wk 6–8

Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.

Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.

HbA1c & Fasting Plasma Glucose

Day 0 + Wk 6–8

Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.

Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.

hs-CRP, Prolactin & CMP

Day 0 + Wk 6–8

Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.

Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

11 Human9 Animal

Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.

Limitations: No placebo control reported. Review article — no new primary data.

2026|Journal of the American Academy of Orthopaedic Surgeons. Global research &amp; reviews
PubMed

BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.

Limitations: No placebo control reported. Review article — no new primary data.

2026|The American journal of sports medicine
PubMed

Co-extraction and analysis of several different peptides such as insulins (human, lispro, aspart, glulisine, tresiba, detemir, glargine, bovine insulin and porcine insulin), growth hormone releasing hormones (sermorelin, CJC-1295 and tesamorelin), insulin-like growth factors (long-R3-IGF-I, R3-IGF-I and Des1-3-IGF-I) and mechano growth factors (human MGF and MGF-Goldspink) with criteria that fulfil the requirements of the WADA documents (TD2022 MRPL) for doping controls. The proof of principle was shown by the analysis of post administration samples after treatment with synthetic insulin analogues.

Limitations: Animal study only — human translation uncertain.

2024|Analytical science advances
PubMed

The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.

Limitations: Animal study only — human translation uncertain.

2023|Analytical biochemistry
PubMed

For the MAX assessment, the average MoD across subjects was 1.9 &#xb1; 3.0% BW, and 2S was 15.8 &#xb1; 9.3% BW. The results of this study show that this sensor technology can be used to obtain accurate measurements of peak walking forces with a basic calibration and consequently open new opportunities to monitor GRF outside of the laboratory.

Limitations: Animal study only — human translation uncertain.

2023|Wearable technologies
PubMed

These were used as reference materials to spike into urine together with commercially available parent peptides and a metabolite of sermorelin (sermorelin(3-29)-NH2 ) to develop a sensitive liquid chromatography-tandem mass spectrometry method for their detection to help prove GHRH administration. Limits of detection of the target peptides were generally 1&#xa0;ng/ml (WADA required performance limit) or less.

Limitations: No placebo control reported.

2022|Drug testing and analysis
PubMed

Stability experiments showed the importance of the proper handling of urine samples to avoid degradation of these peptide hormones, especially for sermorelin and its metabolite which were found to rapidly degrade at temperatures >&#xa0;4&#xa0;&#xb0;C and pH values <&#xa0;7 in accordance with earlier studies. Without the need for specific antibodies, this method may be expanded to cover emerging peptide drugs (&#x2265; ~3&#xa0;kDa), as well as their metabolites in the future to facilitate coverage for this class of prohibited substances.

Limitations: Animal study only — human translation uncertain.

2022|Journal of pharmaceutical and biomedical analysis
PubMed

Here we demonstrate the confirmation of CJC-1295 in equine plasma by LC-MS/MS after immuno-affinity capture and tryptic digestion. Using this method, CJC-1295 was identified down to concentrations as low as 180&#xa0;pg/mL in 1&#xa0;mL of equine plasma.

Limitations: Animal study only — human translation uncertain.

2020|Drug testing and analysis
PubMed

Detection of endogenous equine GHRH necessitated a screening threshold for CJC-1295 in equine plasma of 50&#xa0;pg/mL. The effectiveness of the assay for controlling the illicit use of CJC-1295 was confirmed in equine blood samples after administration in thoroughbred race horses.

Limitations: Animal study only — human translation uncertain.

2019|Drug testing and analysis
PubMed

Comparison with reference standards unequivocally identified the content of the powders as analogs of the growth hormone secretagogues GHRP-2 (Pralmorelin), GHRP-6, Ipamorelin, and modified growth hormone releasing factor (modified GRF 1-29), which can be used as performance-enhancing substances in sports. In all cases, the detected modification involved the addition of an extra glycine amino acid at the N-terminus, and analytical methods targeting growth hormone secretagogues should hence be updated accordingly.

Limitations: Animal study only — human translation uncertain.

2019|Drug testing and analysis
PubMed

Forum users appeared well versed and experienced in the poly use of performance and image drug supplementation. Choice to use CJC-1295 centered on weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing.

Limitations: No placebo control reported. Review article — no new primary data.

2016|Substance use &amp; misuse
PubMed

The method was validated considering the parameters specificity, recovery (11-69%), linearity, imprecision (<25%), limit of detection (5-100 pg in urine, 0.1-2 ng in plasma), and ion suppression. The analysis of administration study samples for insulin degludec, detemir, aspart, and synacthen provided the essential data for the proof-of-principle of the method.

Limitations: No placebo control reported.

2016|Drug testing and analysis
PubMed

The obtained results demonstrate that GHRHs are successfully detected in plasma using an immunoaffinity-mass spectrometry-based method, which can be applied to sports drug testing samples. Further studies are however required and warranted to account for potential species-related differences in metabolism and elimination of the target analytes.

Limitations: No placebo control reported.

2016|Analytical and bioanalytical chemistry
PubMed

For each class of peptides an appropriate antibody and a respective internal standard was implemented ensuring robust analysis conditions. Due to the fast and simple sample preparation procedure (&#x223c;25 samples per day) and the fact that all materials are commercial available, the implementation of the methodology to laboratories from other analytical fields (forensics, pharmacokinetic sciences, etc.) is enabled.

Limitations: No placebo control reported. Review article — no new primary data.

2012|Methods (San Diego, Calif.)
PubMed

CJC-1295 is a releasing factor for growth hormone and is therefore considered a Prohibited Substance under Section S2 of the WADA Prohibited List. This substance has potential performance-enhancing effects, it is readily available, and there is reason to believe that it is being used within the bodybuilding community.

Limitations: Animal study only — human translation uncertain.

2011|Drug testing and analysis
PubMed

Two protein spots that displayed decreased intensities after treatment were identified as an apolipoprotein A1 isoform and a transthyretin isoform. Three protein spots upregulated by CJC-1295 treatment included beta-hemoglobin, a C-terminal fragment of albumin, and a mix of an immunoglobulin fragment and another C-terminal albumin fragment.

Limitations: No placebo control reported.

2010|Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
PubMed

GH secretion was increased after CJC-1295 administration with preserved pulsatility. The frequency and magnitude of GH secretory pulses were unaltered.

Limitations: No placebo control reported.

2007|The Journal of clinical endocrinology and metabolism
PubMed

After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. The estimated half-life of CJC-1295 was 5.8-8.1 d.

Limitations: Standard limitations apply. Check original paper for full discussion.

2006|The Journal of clinical endocrinology and metabolism
PubMed

These findings demonstrate that treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice. The same dose is less effective when administered every 48 or 72 h.

Limitations: Animal study only — human translation uncertain.

2006|American journal of physiology. Endocrinology and metabolism
PubMed

A Western blot analysis of the plasma of a rat injected with CJC-1295 showed the presence of a CJC-1295 immunoreactive species on the band corresponding to serum albumin, appearing after 15 min and remaining in circulation beyond 24 h. These results led to the identification of CJC-1295 as a stable and active hGRF(1-29) analog with an extended plasma half-life.

Limitations: No placebo control reported.

2005|Endocrinology
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Affects hormone levels
  • •Requires medical supervision
  • •Not approved for human use
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get CJC-1295 (No DAC / Mod GRF 1-29), baseline labs & clinician oversight.

Full CJC-1295 (No DAC / Mod GRF 1-29) $/mg comparison →
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy CJC-1295 (No DAC / Mod GRF 1-29): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Polaris Peptides — $6.00/mg (10mg CJC-1295 no DAC / Ipamorelin 5/5mg, $60.00)
  2. 2. Swift Peptides — $6.00/mg (20mg CJC-1295 no DAC / Ipamorelin 10/10mg, $119.99)
  3. 3. Elite Research USA — $7.00/mg (10mg vial, $70.00)

Where is the cheapest place to buy CJC-1295 (No DAC / Mod GRF 1-29)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Polaris Peptides at $6.00/mg (10mg CJC-1295 no DAC / Ipamorelin 5/5mg, $60.00). We compared 5 US suppliers with live, checked prices.

How much does CJC-1295 (No DAC / Mod GRF 1-29) cost per mg?

Verified US domestic prices currently range from $6.00/mg to $10.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is CJC-1295 (No DAC / Mod GRF 1-29) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Popular Stacks

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.